# Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

> **NCT07220759** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 330 (estimated)

## Conditions studied

- Overweight
- Obesity
- Type 2 Diabetes

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** Placebo (matched to Cagrilintide)

## Key facts

- **NCT ID:** NCT07220759
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-05
- **Primary completion:** 2027-05-12
- **Final completion:** 2027-06-30
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07220759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07220759, "Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07220759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*